1
Country: USA | Funding: $209M
Ikena Oncology is developing novel immunometabolic therapies. Its flagship drug IMG-007 is a monoclonal antibody against OX40 with an extended half-life (5 weeks) for patients with immunological, autoimmune and inflammatory diseases. IMG-007 contains a modified Fc region that blocks ADCC function, meaning signaling by activated T cells is weakened without destroying or depleting T cells. This solution has the potential to improve tolerability and increase the range of measurement, leading to the use of higher doses, increased efficacy and improved safety. The company's primary target is atopic dermatitis. In a proof-of-concept clinical trial in patients with moderate to severe atopic dermatitis, three doses of IMG-007 administered over a one-month period resulted in symptom reduction in the majority of patients. Ikena Oncology was acquired by ImageneBio
Ikena Oncology is developing novel immunometabolic therapies. Its flagship drug IMG-007 is a monoclonal antibody against OX40 with an extended half-life (5 weeks) for patients with immunological, autoimmune and inflammatory diseases. IMG-007 contains a modified Fc region that blocks ADCC function, meaning signaling by activated T cells is weakened without destroying or depleting T cells. This solution has the potential to improve tolerability and increase the range of measurement, leading to the use of higher doses, increased efficacy and improved safety. The company's primary target is atopic dermatitis. In a proof-of-concept clinical trial in patients with moderate to severe atopic dermatitis, three doses of IMG-007 administered over a one-month period resulted in symptom reduction in the majority of patients. Ikena Oncology was acquired by ImageneBio
2
Country: USA | Funding: $51.9M
DermaSensor is developing a handheld device for practitioners for detection of skin cancer risk. It is the first FDA-cleared AI-powered skin cancer diagnostic device that enables objective referral prioritization using a 0-10 cancer risk assessment scale. A total of five spectral data points are captured from each skin lesion. The DermaSensor algorithm analyzes the spectral data and provides a skin cancer risk assessment in seconds. The tip of the device reflects and records short bursts of light from the lesion's cellular and subcellular contents. The light is analyzed by a built-in computer, providing information that helps physicians evaluate skin lesions (including melanomas, squamous cell carcinomas and basal cell carcinomas) to determine referral.
DermaSensor is developing a handheld device for practitioners for detection of skin cancer risk. It is the first FDA-cleared AI-powered skin cancer diagnostic device that enables objective referral prioritization using a 0-10 cancer risk assessment scale. A total of five spectral data points are captured from each skin lesion. The DermaSensor algorithm analyzes the spectral data and provides a skin cancer risk assessment in seconds. The tip of the device reflects and records short bursts of light from the lesion's cellular and subcellular contents. The light is analyzed by a built-in computer, providing information that helps physicians evaluate skin lesions (including melanomas, squamous cell carcinomas and basal cell carcinomas) to determine referral.
3
Country: USA | Funding: $1.4B
Kymera Therapeutics is a biotechnology company that specializes in the field of targeted protein degradation.
Kymera Therapeutics is a biotechnology company that specializes in the field of targeted protein degradation.
4
Country: USA | Funding: $656.4M
Astria Therapeutics discovers and develops innovative drugs for treating inflammatory conditions.
Astria Therapeutics discovers and develops innovative drugs for treating inflammatory conditions.
5
Country: USA | Funding: $259.9M
DermTech is a global leader in molecular dermatology, implementing precision medicine methods in the diagnosis and treatment of skin diseases. The company developed DermTech test for the early detection of melanoma and personalized selection of drug therapy. This noninvasive genomic test uses DermTech Smart Stickers to evaluate questionable melanocytic lesions that meet one or more ABCDE criteria. It identifies genomic markers associated with melanoma to differentiate benign lesions from those at higher risk. The test has a negative predictive value of 99%, meaning that a negative test result indicates a 99% probability that the lesion is not melanoma.
DermTech is a global leader in molecular dermatology, implementing precision medicine methods in the diagnosis and treatment of skin diseases. The company developed DermTech test for the early detection of melanoma and personalized selection of drug therapy. This noninvasive genomic test uses DermTech Smart Stickers to evaluate questionable melanocytic lesions that meet one or more ABCDE criteria. It identifies genomic markers associated with melanoma to differentiate benign lesions from those at higher risk. The test has a negative predictive value of 99%, meaning that a negative test result indicates a 99% probability that the lesion is not melanoma.
6
Country: China | Funding: $195M
Connect Biopharmaceuticals is a developer of novel immune modulators for the treatment of serious autoimmune diseases and inflammation.
Connect Biopharmaceuticals is a developer of novel immune modulators for the treatment of serious autoimmune diseases and inflammation.
7
Country: USA | Funding: $185.9M
AnaptysBio is a therapeutic antibody product company and the leader in the use of somatic hypermutation, or SHM, for antibody discovery and optimization. SHM is the body's natural process for generating potent antibodies to fight disease.
AnaptysBio is a therapeutic antibody product company and the leader in the use of somatic hypermutation, or SHM, for antibody discovery and optimization. SHM is the body's natural process for generating potent antibodies to fight disease.
8
Country: USA | Funding: $154.5M
Verrica Pharmaceuticals is a Bay Area pharmaceutical company developing proprietary topical therapies for the treatment of lesional skin diseases such as Verruca vulgaris (common warts and plantar warts) and Molluscum contagiosum.
Verrica Pharmaceuticals is a Bay Area pharmaceutical company developing proprietary topical therapies for the treatment of lesional skin diseases such as Verruca vulgaris (common warts and plantar warts) and Molluscum contagiosum.
9
Country: USA | Funding: $67.4M
Clarify Medical is a developer of a handheld medical device used to treat psoriasis, eczema, and vitiligo .
Clarify Medical is a developer of a handheld medical device used to treat psoriasis, eczema, and vitiligo .
10
Country: UK | Funding: $67M
GetHarley provides personalized end-to-end care for every type of skin.
GetHarley provides personalized end-to-end care for every type of skin.
11
Country: USA | Funding: $56.7M
PathologyWatch delivers an intuitive and easy-to-implement digital pathology solution for dermatologists.
PathologyWatch delivers an intuitive and easy-to-implement digital pathology solution for dermatologists.
12
Country: India | Funding: $25.5M
Cureskin is an AI powered application that provides derma care through mobile devices.
Cureskin is an AI powered application that provides derma care through mobile devices.
13
Country: Switzerland | Funding: $16.2M
OnlineDoctor is an innovative Swiss-based platform that allows the user to diagnosed any skin problems quickly.
OnlineDoctor is an innovative Swiss-based platform that allows the user to diagnosed any skin problems quickly.
14
Country: Denmark | Funding: $12M
Nøie is customised skincare based on individual skin profiles, scientifically proven ingredients, and shared knowledge within a community united by similar issues. Our algorithms harness the power of the crowd to help the individual.
Nøie is customised skincare based on individual skin profiles, scientifically proven ingredients, and shared knowledge within a community united by similar issues. Our algorithms harness the power of the crowd to help the individual.
16
Country: Germany | Funding: €3.5M
The smartphone App Nia, a medically validated companion, gives patients with eczema daily support and offers a comprehensive assistance.
The smartphone App Nia, a medically validated companion, gives patients with eczema daily support and offers a comprehensive assistance.
17
Country: India | Funding: $3.2M
Clinikally is India's first digital skin and hair clinic offering video consults, treatment plans and curated products.
Clinikally is India's first digital skin and hair clinic offering video consults, treatment plans and curated products.
18
Country: Estonia | Funding: €2M
Haut.AI is developing AI algorithms for recognition of skin pathologies. Our developments are based on the algorithms of computer vision and machine learning including deep learning. Our core product is SaaS for skincare. We help our clients:
Haut.AI is developing AI algorithms for recognition of skin pathologies. Our developments are based on the algorithms of computer vision and machine learning including deep learning. Our core product is SaaS for skincare. We help our clients:
19
Country: UK | Funding: $150K
Proton Health eczema solution provider that offers digital applications for reality for health.
Proton Health eczema solution provider that offers digital applications for reality for health.
20
Country: Canada
Triage is an app using AI to instantly screen skin disorders using a smartphone.
Triage is an app using AI to instantly screen skin disorders using a smartphone.
21
Country: UK
Online personalized skin-deep analysis for all skin tones and all genders. The automated analysis report is based on natural light, just as nature sees you.
Online personalized skin-deep analysis for all skin tones and all genders. The automated analysis report is based on natural light, just as nature sees you.
22
Country: Singapore
NOTA mole tracker is a device&app for mapping and checking moles at home. Early diagnosis of skin cancer/melanoma with bioimpedance.
NOTA mole tracker is a device&app for mapping and checking moles at home. Early diagnosis of skin cancer/melanoma with bioimpedance.
23
Country: Netherlands
Gladskin is a Micreos brand,they provide solutions on a deep and thorough understanding of the problems of our customers.
Gladskin is a Micreos brand,they provide solutions on a deep and thorough understanding of the problems of our customers.
